Eight dental lab deals have been announced so far in 2026, one short of the pace set in 2021. That number is getting read as a signal to sell. We think it is a better signal about what makes a lab durable.
What changed in this wave
The last big consolidation cycle ran on a scale thesis. Buy labs, centralize production, pull cost out of the middle, and let the volume do the work. It worked in some cases and produced a lot of unhappy technicians in others.
The 2026 deals look different. The recapitalization of Apex Dental Laboratory Group by LongueVue Capital and Swaney Group Capital in March, and Catalis Dental Lab Partners picking up Revolution Dental Lab, JB Dental Lab and Avaneer Dental Studio, share a common characteristic. The coverage describes buyers underwriting domestic manufacturing capacity and digital capability, and treating both as competitive moats rather than overhead.
That is a real shift. Domestic production went from being the expensive option to being the defensible one, and the tariff environment did most of the work in getting it there.
The part that has nothing to do with selling
Here is why this matters to a lab that will never take a call from a banker.
If buyers are paying a premium for domestic capacity, digital workflow and provable operating performance, those three things are not deal characteristics. They are competitive characteristics. The lab down the road is not going to beat you because it got bought. It is going to beat you if it can quote faster, turn cases faster, and show a doctor a remake rate.
The first two are equipment and process decisions. The third one is where most independent labs quietly lose ground, and it is the cheapest of the three to fix.
The numbers a buyer asks for, and why you need them anyway
Due diligence on a lab is not exotic. It comes down to a handful of questions.
What is the remake rate, and does it break out by technician, by account, and by product? What does AR aging look like past 30, 60 and 90 days? What is unit throughput per technician? Which accounts are growing, and which have quietly shrunk 20% over eighteen months?
Most lab owners have a feel for all of these. Very few can produce the actual figures without a week of spreadsheet archaeology, and the figures that come out of that week describe a lab that no longer exists.
That gap is expensive long before anyone is buying anything. A remake rate that drifts from 4% to 7% costs real money for months before it shows up in a P&L. An account that slides from net 30 to net 75 does the same thing to cash. A technician whose throughput dropped after a workflow change is a problem you want to catch in three weeks, not at year end.
None of that requires a transaction to be worth knowing.
What a good version of this looks like
The labs that handle this well are not running more reports. They are running fewer, and looking at them more often.
A weekly glance at remake rate by account catches quality drift while it is still a conversation and not a lost customer. A live view of AR aging turns collections from a month-end scramble into a Tuesday task. Technician throughput compared week over week tells you whether the new mill actually did what the salesperson said it would.
This is the reason we built EvoDASH into the Evolution suite. Not because dashboards are interesting, but because the interval between when a number goes wrong and when a lab owner finds out is where margin disappears. Shortening that interval is most of the job.
What this means for your lab
You do not need to have an opinion about private equity to take something from this cycle. Take the checklist instead.
Pick the three numbers that would most change a decision you are making this quarter. For most labs that is remake rate, AR past 60, and units per tech. Find out what they are this month, not last year. Then look at them again in thirty days.
If that exercise takes you a week, that is the finding. It should take a minute.
See what this looks like in practice
If you have been on Evolution a while and feel like you are not using everything you have, we do free walkthroughs. If you are evaluating a change, we are glad to show you what real-time lab visibility looks like on your own data. Either way, reach out.
Learn more about ABS and Evolution
Follow ABS on Facebook, Instagram, LinkedIn, and X. Please contact us directly if you’d like to learn more about Evolution dental lab management software.